 |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05669105 |
|
Recruitment Status : **RECRUITING NOW**
First Posted : December 30, 2022 Last Update Posted : December 30, 2022 |
Sponsor:
Information provided by (Responsible Party):
Sanguine Biosciences
Brief Summary:
The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.
| Non Small Cell Lung Cancer | Diagnostic Test: Specimen sample |
| Study Type : | Observational |
| Estimated Enrollment : | 200 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research |
| Actual Study Start Date : | February 19, 2022 |
| Estimated Primary Completion Date : | April 2023 |
| Estimated Study Completion Date : | April 2023 |
- Biospecimen & Clinical Data Collection [ Time Frame: 10 years ]
Collecting biospecimen samples (e.g., whole blood) from participants diagnosed with various active lung cancers so that investigations into the immune response can take place and aid in understanding active lung cancer biomarkers for future early diagnosis and treatment options.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study:  | 18 Years to 100 Years  (Adult, Older Adult) |
| Sexes Eligible for Study: Â | All |
| Accepts Healthy Volunteers: Â | No |
| Sampling Method: Â | Probability Sample |
The study will enroll up to 200 participants. Recruitment will occur through Sanguine advertisements, partnerships with cancer foundations, and cancer centers. Participants may be contacted for future studies.
Inclusion Criteria:
- Participants willing and able to provide written informed consent
- Participants are willing and able to provide appropriate photo identification
- Participant’s age 18 – 100 years old
- Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.)
- Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records
Exclusion Criteria:
- Participants who are pregnant or nursing
- Participants with a known history of HIV, hepatitis, or other infectious diseases
- Participants who have taken an investigational product in the last 30 days
- Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months
- Participants currently enrolled in a clinical trial
- Participants currently in remission
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05669105
| Sanguine Biosciences | |
| Waltham, Massachusetts, United States, 02451 | |
| Contact: Thomas Goslin   818-583-8844   tgoslin@sanguinebio.com   | |
| Principal Investigator: Houman Hemmati, MD Â Â Â Â Â Â | |
Sanguine Biosciences
| Responsible Party: | Sanguine Biosciences |
| ClinicalTrials.gov Identifier: | NCT05669105 Â Â |
| Other Study ID Numbers: | SAN-08877 |
| First Posted: | December 30, 2022 Â Â Key Record Dates |
| Last Update Posted: | December 30, 2022 |
| Last Verified: | December 2022 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Sanguine Biosciences:
| lung cancer NSCLC |
Additional relevant MeSH terms:
| Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
